Stockreport

Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]

Alto Neuroscience, Inc.  (ANRO) 
PDF – Additional Phase 2 studies ongoing: ALTO-101 in schizophrenia and ALTO-100 as an adjunctive treatment in bipolar depression – – Key learnings from ALTO-100 Phase 2b [Read more]